October 1st, 2024 - AzurBio Pharma, specializing in bringing innovative pharmaceutical products to European markets and focusing on rare and serious diseases with unmet medical needs, is announcing ...

The latest investment in the Lebanon site comes after an announcement in May of $5.3 billion earmarked to build production capacity for Lilly’s obesity and diabetes drugs. All told, the company said ...

The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year.

IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.

The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were backing the biotech, then named “Hercules CM NewCo.” ...

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch in 2025.

Threatened with sanctions and loss of its agreement with Medicare and Medicaid, J&J is rolling back a plan to give hospitals after-the-fact rebates for 340B drugs.

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry, and a ...

Cheong points to the broad spectrum of patient demographics in the APAC region for creating substantial opportunities for clinical trial sponsors who are keen to meet enrolment targets at an expedited ...

Among the investors in Aktis’ Series B round were Bristol Myers Squibb, Eli Lilly and Merck & Co., all of which have expanded their involvement in the radiopharma field.